STRATA Skin Sciences Showcases Remarkable Innovations in Dermatology
HORSHAM, Pa. — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a leading name in dermatologic technologies, has taken significant strides in its field by participating at the notable Ibero-Latin American Congress of Dermatology. This event, known as TeraCILAD, brought together experts and practitioners dedicated to enhancing skin health, showcased from November 19 to 22, 2025.
Innovative Products on Display
At TeraCILAD 2025, STRATA highlighted its flagship XTRAC® excimer laser, which is highly regarded for its effectiveness in treating various skin conditions including psoriasis and vitiligo. Alongside this, the company presented the TheraclearX® acne therapy system, which is now commercially available in Mexico, marking a significant expansion for both technologies in the region.
Strong Adoption in Mexico
By the end of 2025, STRATA anticipates more than 12 new recurring accounts for TheraclearX® in Mexico, demonstrating a clear trend among dermatologists towards adopting this innovative, non-drug approach to acne treatment. This shift signifies the growing trust of healthcare professionals in advanced dermatological equipment and solutions offered by STRATA.
Insights from Leading Dermatology Experts
During the conference, Dr. Melissa Lomeli shared her valuable experience as the first user of TheraclearX® in Mexico. Her engaging session, titled “TheraclearX: Rewriting the Protocol for the Treatment of Mild to Moderate Acne,” captivated the audience as she explored the rapid improvements in acne treatment achievable within just one 20-minute session. This narrative captured the imagination of attendees, emphasizing the efficacy of the product.
Dr. Henry Lim, an expert in skin diseases, also presented on the use of XTRAC in treating conditions like vitiligo and psoriasis, further validating the impressive capabilities of STRATA's technologies. His insights reinforced the importance of precision in dermatology and the advantages of using cutting-edge devices.
Setting the Market Context
As TeraCILAD 2025 featured numerous dermatology professionals, STRATA took the opportunity to present clinical outcomes and performance reviews of its technologies. The interest surrounding XTRAC® and TheraclearX® underlined the need for effective treatment options in dermatology, particularly those that do not rely on pharmaceuticals.
Shmuel Gov, STRATA’s Chief Operating Officer, expressed enthusiasm about the high engagement levels observed at the congress regarding both product lines. He noted that dermatologists are actively seeking non-systemic treatments that can seamlessly integrate into their practices, highlighting a growing trend towards innovative solutions within the industry.
Future Strategies for Market Expansion
STRATA Skin Sciences is determined to enhance its reach and availability of advanced dermatological solutions not just in Latin America but also on a global scale. The company’s presence at TeraCILAD is part of a broader strategic vision aimed at collaborating with key opinion leaders in dermatology, providing support through innovative treatment options, and expanding recurring revenue opportunities through device-driven therapies.
Commitment to Sustainable Growth
The early successful placements of TheraclearX® in Mexico mark a positive step towards achieving STRATA's vision of steady revenue streams in this emerging market. CEO Dolev Rafaeli remarked on the potential financial benefits stemming from successful clinic placements, referencing potential annual revenues that can significantly bolster the company's growth prospects.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a prominent medical technology entity dedicated to the development and commercialization of innovative products for in-office treatments aimed at various dermatological conditions. These conditions include psoriasis, vitiligo, and acne, with their notable products including the XTRAC® excimer laser and the TheraclearX® Acne Therapy System.
With a customer-centric approach, STRATA offers these products through a unique Partnership Program that provides clinics with innovative treatment solutions while ensuring support for both practice personnel and ongoing service needs.
Frequently Asked Questions
What are the key products showcased by STRATA at TeraCILAD 2025?
STRATA showcased its XTRAC® excimer laser and TheraclearX® acne therapy system during the event.
How many new accounts does STRATA expect for TheraclearX® in Mexico?
STRATA anticipates over 12 new recurring accounts for TheraclearX® by the end of 2025.
Who presented at TeraCILAD 2025?
Dr. Melissa Lomeli and Dr. Henry Lim were key speakers at the congress, sharing insights on TheraclearX® and XTRAC® respectively.
What is STRATA’s commitment to the dermatology field?
STRATA is committed to providing advanced solutions, supporting dermatologists with innovative treatment options while expanding its market presence.
What potential revenue can clinics expect from STRATA's technology?
Once established, clinics can potentially realize upwards of $30,000 in annual revenue from each STRATA technology placement.
